Westin Miyako Kyoto,
Kyoto, Japan
Here’s a Sneak Peek at a few AsiaTIDES 2019 Confirmed Speakers & Presentations
We've extended the speaker submisssion deadline until September 14
KEYNOTE SPEAKER:
The Discovery of Semaglutide – A Journey from Ala Scan to Structural Design of GLP-1 Analogues
Jesper Lau, Ph.D., Vice President, Protein & Peptide Chemistry, Novo Nordisk A/S, Denmark
OLIGONUCLEOTIDES
New Strategies and Technologies in Oligonucleotide Therapeutic Development
Thazha Prakash, Ph.D., Director, Medicinal Chemistry, Ionis Pharmaceuticals, USA
Anti-FGF2 Aptamer RBM-007 in Phase I/IIa trials for Wet AMD
Yoshikazu Nakamura, Ph.D., President and CEO, RIBOMIC Inc., and Professor Emeritus, The University of Tokyo, Japan
Emerging RNA Therapeutics: Delivery Approaches for mRNA, siRNA and Beyond
Shiro Akinaga, Ph.D., Director, Chief Scientific Officer, AccuRna Inc., Japan
Presentation Title TBA
Muthiah (Mano) Manoharan, Ph.D., Senior Vice President of Drug Discovery, Alnylam Pharmaceuticals
From Stereopurity to Precision Medicine: Optimizing the Properties of Antisense Nucleic Acid Therapeutics
WAVE Lifesciences, Speaker TBA
mRNA THERAPEUTICS
An Introduction to mRNA Therapeutics
Jim Thompson, Ph.D., Head CMC Project Management, Moderna Therapeutics, USA
Novel mRNA Immunotherapies
Robert Jabulowsky, Ph.D., Deputy Head of Project Management, BioNTech AG, Germany
Development of mRNA
Nigel Horscroft, D.Phil., Area Head, Molecular Therapy, CureVac AG, Germany
Optimizing Delivery of mRNA Therapeutics
Peter Lutwyche, Ph.D., Chief Technology Officer, Genevant Sciences Corporation, Canada
REGULATORY CONSIDERATIONS FOR OLIGOS AND PEPTIDES
Regulatory Strategies for Oligonucleotides and Peptides and Updates on the Regulatory Reform at the CFDA
Dan Zhang, M.D., Co-Founder & CEO, Fountain Medical Development, China
Regulatory Considerations on the Development of Peptide and Device Combination Products
Duu-Gong Wu, Ph.D., Senior Director, Regulatory Consulting, PPD (and Former Deputy Division Director of Division of New Drug Chemistry, CDER, FDA), USA
Presentation TBA
David T. Lin, Ph.D., Senior Consultant, Biologics Consulting, (Former Chemistry Team Leader and Former Acting Division Director, Division of New Drug Chemistry, CDER, FDA), USA
NEXT GENERATION LOCKED NUCLEIC ACIDS (LNA+)
Presentation Title TBA
Konrad Bleicher, RNA Therapeutics, Roche Pharma Preclinical Research and Early Development, Roche Innovation Centre Basel, F. Hoffmann-La Roche Ltd., Switzerland
Presentation Title TBA
Satoshi Inoue, Ph.D., Scientist, Bio-functional Molecular Chemistry Group, Ajinomoto Co., Inc., Japan
PEPTIDES
Genetically Encoded Selection of Novel Cyclic and Bicyclic Architectures
Ratmir Derda, Ph.D., Associate Professor, Department of Chemistry, University of Alberta, Canada
Introducing Green and Sustainable Solvents in Liquid Phase Peptide Manufacturing Processes
El Djouhar Rekaï, Ph.D., Head of Development & Manufacturing Process, PolyPeptide Group, Belgium
Peptide Quality Attributes and USP Standards
Ranjan Chakrabarti, Ph.D., Vice President & Head - Global Biologics Lab and Standards, United States Pharmacopeia, India
Cost Efficient Peptide Purification via ZEOsphere DRP Mixed-Mode Chromatography
Jurgen Machielse, Business Development Director, Zeochem AG, Switzerland
Presentation Title TBA
Daniel Samson, Ph.D., Vice President API SPPS, Bachem AG, Switzerland
PEPTIDES (Cont.)
Challenges in Synthesis of the Peptide API
Robert Hagopian, Director Business Development, PolyPeptide Group
Analytical methods, Pre-formulation, and Formulation for Early Phase Development
Christopher Rhodes, Ph.D., President and CEO, Drug Delivery Experts
Toxicology and Bioanalytical Strategies/Phase 1 Strategies
Bruce Morimoto, Ph.D., Vice President, Drug Development-Operations, Alkahest
Similarities and Differences in the Product Development between a Peptide Drug and a Peptide Biologic in the US
Duu-Gong Wu, Ph.D., Senior Director, Regulatory Consulting, PPD (and Former Deputy Division Director of Division of New Drug Chemistry, CDER, FDA), USA